A synergistic interaction between PRMT5 and LSD1 inhibitors in AML - PubMed
6 hours ago
- #AML
- #epigenetics
- #synergistic-inhibition
- PRMT5, a methyltransferase, is a therapeutic target in AML but complete inhibition is toxic.
- A targeted screen identified synthetic lethality between PRMT5 and LSD1 inhibition in AML.
- Combined inhibition reshapes the transcriptome, promoting differentiation, growth inhibition, and apoptosis in a p53-dependent manner.
- New dual compounds inhibiting both enzymes were generated, replicating the synergistic effects.
- The study reveals convergence of PRMT5- and LSD1-regulated targets, suggesting new therapeutic strategies.